In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—including Celgene’s Otezla, three IL-17 inhibitors, and two IL-23 inhibitors—is altering the market landscape. The oral agent Otezla has been successfully carving out a space in biologics-naive patients. The more-effective biologics, Novartis’s Cosentyx and Eli Lilly’s TaltzIL-17 inhibitors, are threatening the first-line dominance of TNF-α inhibitors, and Janssen’s IL-23 inhibitor Tremfya is likely to follow. With the recent entry of biosimilars and another IL-23 inhibitor in late-phase development, marketers of psoriasis therapies will learn how they can best overcome the formulary and uptake challenges facing current and emerging therapies in this increasingly competitive market.
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.